Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 11193–11198 | Cite as

A4383C and C76G SNP in Cathepsin B is respectively associated with the high risk and tumor size of hepatocarcinoma

Research Article

Abstract

Single nucleotide polymorphism (SNP) in some genes is a candidate for having or developing a cancer. Cathepsin B (CTSB) is considered to be the biomarker of cancers. The study aimed to evaluate the impacts of three SNPs in CTSB gene on the risk and progress of hepatocellular carcinoma (HCC). The SNPs of CTSB C76G (rs12338), CTSB A4383C (rs13332), and CTSB A8422G (rs8898) from 135 patients with HCC and 520 control participants in Taiwan were determined by real-time PCR. Through analyzing by statistics, we found that the polymorphism of rs13332 was significantly associated to the risk of HCC cancer; a significantly high frequent tumor size development was observed in HCC patients carrying rs12338 polymorphic genotype than those carrying ancestral genotype. The SNPs of rs12338, rs13332, and rs8898 were irrelevant to the frequencies of HCC clinical status and the levels of HCC clinicopathological markers. In conclusions, CTSB A4383C SNP is observed modestly more often in patients who developed HCC than in healthy controls and might be associated with the risk of HCC. The association between CTSB C76G SNP and greater tumor size may warrant further study in regards to the biology of HCC.

Keywords

Cathepsin B Diagnostic marker Hepatocellular carcinoma Single nucleotide polymorphism 

Abbreviations

AOR

Adjusted odds ratio

CI

Confidence interval

CTSB

Cathepsin B

HCC

Hepatocellular carcinoma

PCR

Polymerase chain reaction

SNP

Single nucleotide polymorphism

Notes

Acknowledgments

This study was supported by a research grant from Central Region Hospital Alliance, Ministry of Health and Welfare, Taiwan (2013 project number: 10215).

Conflicts of interest

None

References

  1. 1.
    Shastry BS. SNP alleles in human disease and evolution. J Hum Genet. 2002;47:561–6.PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. The world health report. Geneva: WHO; 2010.Google Scholar
  3. 3.
    Feitelson MA. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma. Cancer Lett. 2006;239:10–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematol Am Soc Hematol Educ Program 2006; 375–80. Google Scholar
  5. 5.
    Yano Y, Yamashita F, Kuwaki K, et al. Clinical features of hepatitis C virus related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int. 2006;26:789–95.PubMedCrossRefGoogle Scholar
  6. 6.
    Hsieh YS, Tsai CM, Yeh CB, et al. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol. 2012;19:S625–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339–46.PubMedCrossRefGoogle Scholar
  8. 8.
    Weng CJ, Hsieh YH, Tsai CM, et al. Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1808–15.PubMedCrossRefGoogle Scholar
  9. 9.
    Weng CJ, Tsai CM, Chen YC, et al. Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 2010;17:3394–401.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen TY, Li YC, Liu YF, et al. Role of MMP14 gene polymorphisms in susceptibiliy and pathological development to hepatocellular carcinoma. Ann Surg Oncol. 2011;18:2348–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113–35.PubMedCrossRefGoogle Scholar
  12. 12.
    Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Investig. 2005;52:1–9.CrossRefGoogle Scholar
  13. 13.
    Erdem NF, Carlson ER, Gerard DA, Ichiki AT. Characterization of 3 oral squamous cell carcinoma cell lines with different invasion and/or metastatic potentials. J Oral Maxillofac Surg. 2007;65:1725–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Vigneswaran N, Zhao W, Dassanayake A, et al. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum Pathol. 2000;31:931–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Wu W, Tang X, Hu W, et al. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 2002;19:319–26.PubMedCrossRefGoogle Scholar
  16. 16.
    Kawasaki G, Kato Y, Mizuno A. Cathepsin expression in oral squamous cell carcinoma: relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:446–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Roshy S, Sloane BF, Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 2003;22:271–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Wickramasinghe NS, Nagaraj NS, Vigneswaran N, Zacharias W. Cathepsin B promotes both motility and invasiveness of oral carcinoma cells. Arch Biochem Biophys. 2005;436:187–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Podgorski I, Sloane BF. Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp. 2003;70:263–76.PubMedGoogle Scholar
  20. 20.
    Weiss FU, Behn CO, Simon P, et al. Cathepsin B gene polymorphism Val26 is not associated with idiopathic chronic pancreatitis in European patients. Gut. 2007;56:1322–3.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Stiblar-Martincic D, Hajdinjak T. Polymorphism L26V in the cathepsin B gene may be associated with a risk of prostate cancer and differentiation. J Int Med Res. 2009;37:1604–10.PubMedCrossRefGoogle Scholar
  22. 22.
    Chen MK, Su SC, Lin CW, et al. Cathepsin B SNPs elevate the pathological development of oral cancer and raise the susceptibility to carcinogen-mediated oral cancer. Hum Genet. 2012;131:1861–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  24. 24.
    Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–308.PubMedCrossRefGoogle Scholar
  25. 25.
    Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer. 2002;98:257–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Tsai MC, Kee KM, Chen YD, et al. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBVendemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol. 2007;22:92–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Akkiz H, Bayram S, Bekar A, et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case–control study. Cancer Epidemiol. 2009;33:261–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Chang CC, Chen SC, Hsieh YH, et al. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma. Clin Chem Lab Med. 2009;47:412–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol. 2000;10:185–200.PubMedCrossRefGoogle Scholar
  30. 30.
    Keppler D, Sameni M, Moin K, et al. Tumor progression and angiogenesis: cathepsin B & Co. Biochem Cell Biol. 1996;74:799–810.PubMedCrossRefGoogle Scholar
  31. 31.
    Warwas M, Haczynska H, Gerber J, Nowak M. Cathepsin B-like activity as a serum tumor marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem. 1997;35:301–4.PubMedGoogle Scholar
  32. 32.
    Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta. 2000;1477:98–111.PubMedCrossRefGoogle Scholar
  33. 33.
    Fedorowski A, Steciwko A, Rabczynski J. Serum cathepsin B activity during regression of Morris hepatoma 5123D. Med Sci Monit. 2004;10:BR144–50.PubMedGoogle Scholar
  34. 34.
    Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med. 1996;21:641–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Mansouri A, Fromenty B, Berson A, et al. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patients. J Hepatol. 1997;27:96–102.PubMedCrossRefGoogle Scholar
  36. 36.
    Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000;15:1356–61.PubMedCrossRefGoogle Scholar
  37. 37.
    Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang BE, Ma WM, Sulaiman A, et al. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. J Med Virol. 2002;67:394–400.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Tsung-Po Chen
    • 1
    • 2
  • Shun-Fa Yang
    • 1
    • 2
  • Chiao-Wen Lin
    • 3
    • 4
  • Hsiang-Lin Lee
    • 1
    • 5
  • Chiung-Man Tsai
    • 1
    • 6
  • Chia-Jui Weng
    • 7
  1. 1.Institute of MedicineChung Shan Medical UniversityTaichungTaiwan
  2. 2.Department of Medical ResearchChung Shan Medical University HospitalTaichungTaiwan
  3. 3.Institute of Oral SciencesChung Shan Medical UniversityTaichungTaiwan
  4. 4.Department of DentistryChung Shan Medical University HospitalTaichungTaiwan
  5. 5.Department of SurgeryChung Shan Medical University HospitalTaichungTaiwan
  6. 6.Ministry of Health and WelfareTainan HospitalTainan CityTaiwan
  7. 7.Department of Living Services IndustryTainan University of TechnologyTainan CityTaiwan

Personalised recommendations